{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:46:32Z","timestamp":1791953192380,"version":"4.3.4"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long non-coding RNAs (lncRNAs) regulate multiple cellular processes and are involved in the development and progression of human cancers, including renal cell carcinoma (RCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Genome-wide DNA methylation profiling using Illumina EPIC arrays was performed to identify differentially methylated regions (DMR) associated with metastatic RCC. Candidate loci within\n                      <jats:italic>LINC01354<\/jats:italic>\n                      and\n                      <jats:italic>LINC01510<\/jats:italic>\n                      were validated by pyrosequencing in 145 primary RCC tissues, 124 paired tumor-adjacent normal tissues (adNs), and 194 metastatic tissue samples obtained from 101 patients with metastatic RCC. In addition, data from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma Collection (TCGA-KIRC) were analyzed in silico to assess the clinical relevance of DNA methylation (DNAm) and its association with gene expression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Hypermethylation across all analyzed CpG sites at both loci was associated with high-stage (\u2265\u2009T3;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.001) and high-grade (\u2265\u2009G3;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.003) RCC and was markedly increased in metastatic tissues compared with localized primary tumors (\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). In addition, primary tumors from patients with distant metastases (M+) showed significantly higher methylation at PS_307-CG1 within\n                      <jats:italic>LINC01510<\/jats:italic>\n                      than tumors from patients without distant metastases (M0;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.031). Analyses of TCGA-KIRC data confirmed associations of increased methylation with adverse clinicopathological features and reduced gene expression, supporting a potential role for epigenetic silencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our data provide further insight into the epigenetic alterations associated with RCC progression by demonstrating tumor- and metastasis-associated hypermethylation at the\n                      <jats:italic>LINC01354<\/jats:italic>\n                      and\n                      <jats:italic>LINC01510<\/jats:italic>\n                      loci. The association of hypermethylation with advanced disease and metastatic tissues, together with the observed inverse relationship between methylation and expression, suggests that epigenetic inactivation of these lncRNAs may contribute to RCC progression. DNAm at these loci may therefore represent a potential biomarker of aggressive disease.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13148-026-02252-4","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:43:51Z","timestamp":1791927831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metastasis-associated DNA methylation of the lncRNAs LINC01354 and LINC01510 in clear cell renal cell carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Pouriya","family":"Faraj Tabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga Mareike","family":"Schimansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Rafea","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hennenlotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Tezval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Antonius","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Serth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2252_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","volume":"75","author":"U Capitanio","year":"2019","unstructured":"Capitanio U, Bensalah K, Bex A, Boorjian SA, Bray F, Coleman J, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75:74\u201384. https:\/\/doi.org\/10.1016\/j.eururo.2018.08.036.","journal-title":"Eur Urol"},{"key":"2252_CR2","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0140-6736(09)60229-4","volume":"373","author":"BI Rini","year":"2009","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119\u201332. https:\/\/doi.org\/10.1016\/s0140-6736(09)60229-4.","journal-title":"Lancet"},{"key":"2252_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","volume":"49","author":"J Ferlay","year":"2012","unstructured":"Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JWW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2012;49:1374\u2013403. https:\/\/doi.org\/10.1016\/j.ejca.2012.12.027.","journal-title":"Eur J Cancer"},{"key":"2252_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","volume":"36","author":"SH Rossi","year":"2018","unstructured":"Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36:1341\u201353. https:\/\/doi.org\/10.1007\/s00345-018-2286-7.","journal-title":"World J Urol"},{"key":"2252_CR5","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1056\/nejmoa2313906","volume":"391","author":"TK Choueiri","year":"2024","unstructured":"Choueiri TK, Powles T, Peltola K, Velasco G, Burotto M, Suarez C, et al. Belzutifan versus everolimus for advanced renal-cell carcinoma. N Engl J Med. 2024;391:710\u201321. https:\/\/doi.org\/10.1056\/nejmoa2313906.","journal-title":"N Engl J Med"},{"key":"2252_CR6","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/s1470-2045(25)00099-3","volume":"26","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan R, Iliopoulos O, Beckermann KE, Narayan V, Maughan BL, Oudard S, et al. Belzutifan for von Hippel-Lindau disease-associated renal cell carcinoma and other neoplasms (LITESPARK-004): 50 months follow-up from a single-arm, phase 2 study. Lancet Oncol. 2025;26:571\u201382. https:\/\/doi.org\/10.1016\/s1470-2045(25)00099-3.","journal-title":"Lancet Oncol"},{"key":"2252_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/nejmoa2518245","volume":"395","author":"TK Choueiri","year":"2026","unstructured":"Choueiri TK, Motzer RJ, Karam JA, Yip W, Su\u00e1rez C, Ye D, et al. Adjuvant pembrolizumab plus belzutifan for renal-cell carcinoma. N Engl J Med. 2026;395:32\u201343. https:\/\/doi.org\/10.1056\/nejmoa2518245.","journal-title":"N Engl J Med"},{"key":"2252_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1200\/edbk_201215","volume":"38","author":"J Graham","year":"2018","unstructured":"Graham J, Heng DYC, Brugarolas J, Vaishampayan U. Personalized management of advanced kidney cancer. Am Soc Clin Oncol Educ Book. 2018;38:330\u201341. https:\/\/doi.org\/10.1200\/edbk_201215.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2252_CR9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.euo.2018.08.023","volume":"2","author":"HD Patel","year":"2019","unstructured":"Patel HD, Gupta M, Joice GA, Srivastava A, Alam R, Allaf ME, et al. Clinical stage migration and survival for renal cell carcinoma in the United States. Eur Urol Oncol. 2019;2:343\u20138. https:\/\/doi.org\/10.1016\/j.euo.2018.08.023.","journal-title":"Eur Urol Oncol"},{"key":"2252_CR10","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1007\/s00345-018-2309-4","volume":"36","author":"T Klatte","year":"2018","unstructured":"Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol. 2018;36:1943\u201352. https:\/\/doi.org\/10.1007\/s00345-018-2309-4.","journal-title":"World J Urol"},{"key":"2252_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.path.2008.08.003","volume":"2","author":"SJ Sirintrapun","year":"2009","unstructured":"Sirintrapun SJ, Parwani AV. Molecular pathology of the genitourinary tract: molecular pathology of kidney and testes. Surg Pathol Clin. 2009;2:199\u2013223. https:\/\/doi.org\/10.1016\/j.path.2008.08.003.","journal-title":"Surg Pathol Clin"},{"key":"2252_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1177\/10668969241256111","volume":"33","author":"BG Nezami","year":"2024","unstructured":"Nezami BG, MacLennan GT. Clear cell renal cell carcinoma: a comprehensive review of its histopathology, genetics, and differential diagnosis. Int J Surg Pathol. 2024;33:265\u201380. https:\/\/doi.org\/10.1177\/10668969241256111.","journal-title":"Int J Surg Pathol"},{"key":"2252_CR13","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.eucr.2019.100989","volume":"27","author":"J Walton","year":"2019","unstructured":"Walton J, Li J, Clifton MM, Mori RL, Park AM, Sumfest JM. Metastatic clear cell renal cell carcinoma to the forearm without identifiable primary renal mass. Urol Case Rep. 2019;27:100989. https:\/\/doi.org\/10.1016\/j.eucr.2019.100989.","journal-title":"Urol Case Rep"},{"key":"2252_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","volume":"499","author":"CJ Creighton","year":"2013","unstructured":"Creighton CJ, Morgan M, Gunaratne PH, Wheeler DA, Gibbs RA, Robertson AG, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43\u20139. https:\/\/doi.org\/10.1038\/nature12222.","journal-title":"Nature"},{"key":"2252_CR15","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/1078-0432.ccr-12-3886","volume":"19","author":"AA Hakimi","year":"2013","unstructured":"Hakimi AA, Ostrovnaya I, Reva B, Schultz N, Chen Y-B, Gonen M, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013;19:3259\u201367. https:\/\/doi.org\/10.1158\/1078-0432.ccr-12-3886.","journal-title":"Clin Cancer Res"},{"key":"2252_CR16","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/ng.2708","volume":"45","author":"AA Hakimi","year":"2013","unstructured":"Hakimi AA, Pham CG, Hsieh JJ. A clear picture of renal cell carcinoma. Nat Genet. 2013;45:849\u201350. https:\/\/doi.org\/10.1038\/ng.2708.","journal-title":"Nat Genet"},{"key":"2252_CR17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet. 2013;45:860\u20137. https:\/\/doi.org\/10.1038\/ng.2699.","journal-title":"Nat Genet"},{"key":"2252_CR18","doi-asserted-by":"publisher","first-page":"11190","DOI":"10.3390\/ijms231911190","volume":"23","author":"J Serth","year":"2022","unstructured":"Serth J, Peters I, Katzendorn O, Dang TN, Moog J, Balli Z, et al. Identification of a novel renal metastasis associated CpG-based DNA methylation signature (RMAMS). Int J Mol Sci. 2022;23:11190. https:\/\/doi.org\/10.3390\/ijms231911190.","journal-title":"Int J Mol Sci"},{"key":"2252_CR19","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.3390\/cancers17132204","volume":"17","author":"PF Tabrizi","year":"2025","unstructured":"Tabrizi PF, Schimansky I, Peters I, Hennenlotter J, Tezval H, Kuczyk MA, et al. Metastasis-specific CpG island DNA hypermethylation of the long non-coding RNA gene 00404 in renal cell carcinoma. Cancers. 2025;17:2204. https:\/\/doi.org\/10.3390\/cancers17132204.","journal-title":"Cancers"},{"key":"2252_CR20","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3727\/096504016x14549667334007","volume":"23","author":"J Li","year":"2016","unstructured":"Li J, Meng H, Bai Y, Wang K. Regulation of lncRNA and its role in cancer metastasis. Oncol Res. 2016;23:205\u201317. https:\/\/doi.org\/10.3727\/096504016x14549667334007.","journal-title":"Oncol Res"},{"key":"2252_CR21","doi-asserted-by":"publisher","first-page":"e202009045","DOI":"10.1083\/jcb.202009045","volume":"220","author":"MC Bridges","year":"2020","unstructured":"Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2020;220:e202009045. https:\/\/doi.org\/10.1083\/jcb.202009045.","journal-title":"J Cell Biol"},{"key":"2252_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.semcancer.2020.12.012","volume":"75","author":"EM McCabe","year":"2021","unstructured":"McCabe EM, Rasmussen TP. LncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions. Semin Cancer Biol. 2021;75:38\u201348. https:\/\/doi.org\/10.1016\/j.semcancer.2020.12.012.","journal-title":"Semin Cancer Biol"},{"key":"2252_CR23","doi-asserted-by":"publisher","first-page":"11887","DOI":"10.1007\/s13277-014-2453-4","volume":"35","author":"Y Wu","year":"2014","unstructured":"Wu Y, Liu J, Zheng Y, You L, Kuang D, Liu T. Suppressed expression of long non-coding RNA HOTAIR inhibits proliferation and tumourigenicity of renal carcinoma cells. Tumor Biol. 2014;35:11887\u201394. https:\/\/doi.org\/10.1007\/s13277-014-2453-4.","journal-title":"Tumor Biol"},{"key":"2252_CR24","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1158\/1535-7163.mct-14-0245","volume":"13","author":"G Yu","year":"2014","unstructured":"Yu G, Yao W, Gumireddy K, Li A, Wang J, Xiao W, et al. Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression. Mol Cancer Ther. 2014;13:3086\u201397. https:\/\/doi.org\/10.1158\/1535-7163.mct-14-0245.","journal-title":"Mol Cancer Ther"},{"key":"2252_CR25","doi-asserted-by":"publisher","first-page":"38005","DOI":"10.18632\/oncotarget.5357","volume":"6","author":"H Xiao","year":"2015","unstructured":"Xiao H, Tang K, Liu P, Chen K, Hu J, Zeng J, et al. LncRNA MALAT1 functions as a competing endogenous RNA to regulate ZEB2 expression by sponging miR-200s in clear cell kidney carcinoma. Oncotarget. 2015;6:38005\u201315. https:\/\/doi.org\/10.18632\/oncotarget.5357.","journal-title":"Oncotarget"},{"key":"2252_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12935-018-0652-6","volume":"18","author":"B Chen","year":"2018","unstructured":"Chen B, Wang C, Zhang J, Zhou Y, Hu W, Guo T. New insights into long noncoding RNAs and pseudogenes in prognosis of renal cell carcinoma. Cancer Cell Int. 2018;18:157. https:\/\/doi.org\/10.1186\/s12935-018-0652-6.","journal-title":"Cancer Cell Int"},{"key":"2252_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13046-019-1150-y","volume":"38","author":"J Li","year":"2019","unstructured":"Li J, He M, Xu W, Huang S. LINC01354 interacting with hnRNP-D contributes to the proliferation and metastasis in colorectal cancer through activating Wnt\/\u03b2-catenin signaling pathway. J Exp Clin Cancer Res. 2019;38:161. https:\/\/doi.org\/10.1186\/s13046-019-1150-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"2252_CR28","doi-asserted-by":"publisher","first-page":"19482","DOI":"10.1002\/jcb.29252","volume":"120","author":"Y Pan","year":"2019","unstructured":"Pan Y, Song Y, Cheng L, Xu H, Liu J. Analysis of methylation\u2010driven genes for predicting the prognosis of patients with head and neck squamous cell carcinoma. J Cell Biochem. 2019;120:19482\u201395. https:\/\/doi.org\/10.1002\/jcb.29252.","journal-title":"J Cell Biochem"},{"key":"2252_CR29","doi-asserted-by":"publisher","first-page":"102058","DOI":"10.1016\/j.omtn.2023.102058","volume":"34","author":"J Yin","year":"2023","unstructured":"Yin J, Ding N, Yu J, Wang Z, Fu L, Li Y, et al. Systematic analysis of DNA methylation-mediated TF dysregulation on lncRNAs reveals critical roles in tumor immunity. Mol Ther Nucleic Acids. 2023;34:102058. https:\/\/doi.org\/10.1016\/j.omtn.2023.102058.","journal-title":"Mol Ther Nucleic Acids"},{"key":"2252_CR30","doi-asserted-by":"publisher","first-page":"D1331","DOI":"10.1093\/nar\/gkaf1250","volume":"54","author":"J Casper","year":"2026","unstructured":"Casper J, Speir ML, Raney BJ, Perez G, Nassar LR, Lee CM, et al. The UCSC Genome Browser database: 2026 update. Nucleic Acids Res. 2026;54:D1331\u20135. https:\/\/doi.org\/10.1093\/nar\/gkaf1250.","journal-title":"Nucleic Acids Res"},{"key":"2252_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bbrc.2018.08.167","volume":"505","author":"B Ma","year":"2018","unstructured":"Ma B, Zhang J, Zhou W, Chu C, Zhao C, Zhang Z, et al. LINC01510 suppresses cell proliferation and invasion by inhibiting Wnt\/\u03b2-catenin signaling in renal cell carcinoma. Biochem Biophys Res Commun. 2018;505:7\u201312. https:\/\/doi.org\/10.1016\/j.bbrc.2018.08.167.","journal-title":"Biochem Biophys Res Commun"},{"key":"2252_CR32","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.biopha.2018.10.136","volume":"109","author":"J Li","year":"2019","unstructured":"Li J, Wei L. Increased expression of LINC01510 predicts poor prognosis and promotes malignant progression in human non-small cell lung cancer. Biomed Pharmacother. 2019;109:519\u201329. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.136.","journal-title":"Biomed Pharmacother"},{"key":"2252_CR33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-2520","author":"R Esposito","year":"2019","unstructured":"Esposito R, Esposito D, Pallante P, Fusco A, Ciccodicola A, Costa V. Oncogenic properties of the antisense lncRNA COMET in BRAF- and RET-driven papillary thyroid carcinomas. Cancer Res. 2019. https:\/\/doi.org\/10.1158\/0008-5472.can-18-2520.","journal-title":"Cancer Res"},{"key":"2252_CR34","doi-asserted-by":"publisher","first-page":"7710","DOI":"10.26355\/eurrev_201811_16392","volume":"22","author":"J-F Zhou","year":"2018","unstructured":"Zhou J-F, Wang H-G, Ma T-H, Yan W, Wu S-N, Shi Y-T, et al. Long noncoding RNA LINC01510 is highly expressed in colorectal cancer and predicts favorable prognosis. Eur Rev M\u00e9d Pharmacol Sci. 2018;22:7710\u20135. https:\/\/doi.org\/10.26355\/eurrev_201811_16392.","journal-title":"Eur Rev M\u00e9d Pharmacol Sci."},{"key":"2252_CR35","doi-asserted-by":"publisher","first-page":"9597","DOI":"10.18632\/aging.102407","volume":"11","author":"G Cheng","year":"2019","unstructured":"Cheng G, Liu D, Liang H, Yang H, Chen K, Zhang X. A cluster of long non-coding RNAs exhibit diagnostic and prognostic values in renal cell carcinoma. Aging (Albany NY). 2019;11:9597\u2013615. https:\/\/doi.org\/10.18632\/aging.102407.","journal-title":"Aging (Albany NY)"},{"key":"2252_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12935-018-0503-5","volume":"18","author":"C Cen","year":"2018","unstructured":"Cen C, Li J, Liu J, Yang M, Zhang T, Zuo Y, et al. Long noncoding RNA LINC01510 promotes the growth of colorectal cancer cells by modulating MET expression. Cancer Cell Int. 2018;18:45. https:\/\/doi.org\/10.1186\/s12935-018-0503-5.","journal-title":"Cancer Cell Int"},{"key":"2252_CR37","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/0008-5472.can-20-0821","volume":"82","author":"AS Pal","year":"2022","unstructured":"Pal AS, Agredo A, Lanman NA, Son J, Sohal IS, Bains M, et al. Loss of KMT5C promotes EGFR inhibitor resistance in NSCLC via LINC01510-mediated upregulation of METKMT5C mediates EGFR inhibitor sensitivity. Cancer Res. 2022;82:OF1-14. https:\/\/doi.org\/10.1158\/0008-5472.can-20-0821.","journal-title":"Cancer Res"},{"key":"2252_CR38","unstructured":"COMETT Gene - GeneCards | COMETT RNA Gene. https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=COMETT&keywords=LINC01510.%20In:%20COMETT. Accessed 20 Oct 2025"},{"key":"2252_CR39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/cancers14010039","volume":"14","author":"O Katzendorn","year":"2021","unstructured":"Katzendorn O, Peters I, Dubrowinskaja N, Moog JM, Reese C, Tezval H, et al. DNA methylation in INA, NHLH2, and THBS4 is associated with metastatic disease in renal cell carcinoma. Cancers. 2021;14:39. https:\/\/doi.org\/10.3390\/cancers14010039.","journal-title":"Cancers"},{"key":"2252_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13148-020-0823-x","volume":"12","author":"J Serth","year":"2020","unstructured":"Serth J, Peters I, Dubrowinskaja N, Reese C, Albrecht K, Klintschar M, et al. Age-, tumor-, and metastatic tissue-associated DNA hypermethylation of a T-box brain 1 locus in human kidney tissue. Clin Epigenetics. 2020;12:33. https:\/\/doi.org\/10.1186\/s13148-020-0823-x.","journal-title":"Clin Epigenetics"},{"key":"2252_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/1471-2407-10-503","volume":"10","author":"S Waalkes","year":"2010","unstructured":"Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, Becker JU, et al. Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer. 2010;10:503. https:\/\/doi.org\/10.1186\/1471-2407-10-503.","journal-title":"BMC Cancer"},{"key":"2252_CR42","doi-asserted-by":"publisher","first-page":"3861","DOI":"10.3892\/or.2018.6732","volume":"40","author":"I Peters","year":"2018","unstructured":"Peters I, Dubrowinskaja N, Hennenlotter J, Antonopoulos WI, Klot C-AJV, Tezval H, et al. DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients. Oncol Rep. 2018;40:3861\u20138. https:\/\/doi.org\/10.3892\/or.2018.6732.","journal-title":"Oncol Rep"},{"key":"2252_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/bjc.2012.537","volume":"108","author":"K Gebauer","year":"2013","unstructured":"Gebauer K, Peters I, Dubrowinskaja N, Hennenlotter J, Abbas M, Scherer R, et al. Hsa-mir-124-3 CpG island methylation is associated with advanced tumours and disease recurrence of patients with clear cell renal cell carcinoma. Br J Cancer. 2013;108:131\u20138. https:\/\/doi.org\/10.1038\/bjc.2012.537.","journal-title":"Br J Cancer"},{"key":"2252_CR44","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.3892\/or.2019.7305","volume":"42","author":"M Mazdak","year":"2019","unstructured":"Mazdak M, Tezval H, Callauch JC, Dubrowinskaja N, Peters I, Bokemeyer C, et al. DNA methylation of sarcosine dehydrogenase (SARDH) loci as a prognosticator for renal cell carcinoma. Oncol Rep. 2019;42:2159\u201368. https:\/\/doi.org\/10.3892\/or.2019.7305.","journal-title":"Oncol Rep"},{"key":"2252_CR45","doi-asserted-by":"publisher","first-page":"e0163873","DOI":"10.1371\/journal.pone.0163873","volume":"11","author":"H Tezval","year":"2016","unstructured":"Tezval H, Dubrowinskaja N, Peters I, Reese C, Serth K, Atschekzei F, et al. Tumor specific epigenetic silencing of corticotropin releasing hormone -binding protein in renal cell carcinoma: association of hypermethylation and metastasis. PLoS ONE. 2016;11:e0163873. https:\/\/doi.org\/10.1371\/journal.pone.0163873.","journal-title":"PLoS ONE"},{"key":"2252_CR46","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4161\/epi.19614","volume":"7","author":"F Atschekzei","year":"2012","unstructured":"Atschekzei F, Hennenlotter J, J\u00e4nisch S, Gro\u00dfhennig A, Tr\u00e4nkenschuh W, Waalkes S, et al. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. Epigenetics. 2012;7:447\u201357. https:\/\/doi.org\/10.4161\/epi.19614.","journal-title":"Epigenetics"},{"key":"2252_CR47","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/bioinformatics\/btu049","volume":"30","author":"MJ Aryee","year":"2014","unstructured":"Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays. Bioinformatics. 2014;30:1363\u20139. https:\/\/doi.org\/10.1093\/bioinformatics\/btu049.","journal-title":"Bioinformatics"},{"key":"2252_CR48","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1093\/bioinformatics\/btw691","volume":"33","author":"J-P Fortin","year":"2017","unstructured":"Fortin J-P, Triche TJ, Hansen KD. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. Bioinformatics. 2017;33:558\u201360. https:\/\/doi.org\/10.1093\/bioinformatics\/btw691.","journal-title":"Bioinformatics"},{"key":"2252_CR49","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/ije\/dyr238","volume":"41","author":"AE Jaffe","year":"2012","unstructured":"Jaffe AE, Murakami P, Lee H, Leek JT, Fallin MD, Feinberg AP, et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol. 2012;41:200\u20139. https:\/\/doi.org\/10.1093\/ije\/dyr238.","journal-title":"Int J Epidemiol"},{"key":"2252_CR50","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico A, Silva TC, Olsen C, Garofano L, Cava C, Garolini D, et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44:e71\u2013e71. https:\/\/doi.org\/10.1093\/nar\/gkv1507.","journal-title":"Nucleic Acids Res"},{"key":"2252_CR51","doi-asserted-by":"publisher","first-page":"D326","DOI":"10.1093\/nar\/gkab997","volume":"50","author":"J Kang","year":"2021","unstructured":"Kang J, Tang Q, He J, Li L, Yang N, Yu S, et al. RNAInter v4.0: RNA interactome repository with redefined confidence scoring system and improved accessibility. Nucleic Acids Res. 2021;50:D326\u201332. https:\/\/doi.org\/10.1093\/nar\/gkab997.","journal-title":"Nucleic Acids Res"},{"key":"2252_CR52","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1039\/c5mb00663e","volume":"12","author":"G Yu","year":"2015","unstructured":"Yu G, He Q-Y. ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization. Mol Biosyst. 2015;12:477\u20139. https:\/\/doi.org\/10.1039\/c5mb00663e.","journal-title":"Mol Biosyst"},{"key":"2252_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"Ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H. Ggplot2: elegant graphics for data analysis. 1st ed. Springer; 2016.","edition":"1st ed"},{"key":"2252_CR54","unstructured":"Pedersen TL. patchwork: The Composer of Plots. CRAN; 2025. https:\/\/CRAN.R-project.org\/package=patchwork"},{"key":"2252_CR55","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2024."},{"key":"2252_CR56","unstructured":"RStudio Team. RStudio: integrated development environment for R. Boston, MA, USA: RStudio; 2022."},{"key":"2252_CR57","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41568-021-00353-1","volume":"21","author":"SJ Liu","year":"2021","unstructured":"Liu SJ, Dang HX, Lim DA, Feng FY, Maher CA. Long noncoding RNAs in cancer metastasis. Nat Rev Cancer. 2021;21:446\u201360. https:\/\/doi.org\/10.1038\/s41568-021-00353-1.","journal-title":"Nat Rev Cancer"},{"key":"2252_CR58","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3892\/ijo.2016.3609","volume":"49","author":"W Zhao","year":"2016","unstructured":"Zhao W, Zhou J, Deng Z, Gao Y, Cheng Y. SPOP promotes tumor progression via activation of \u03b2-catenin\/TCF4 complex in clear cell renal cell carcinoma. Int J Oncol. 2016;49:1001\u20138. https:\/\/doi.org\/10.3892\/ijo.2016.3609.","journal-title":"Int J Oncol"},{"key":"2252_CR59","doi-asserted-by":"publisher","first-page":"e0146505","DOI":"10.1371\/journal.pone.0146505","volume":"11","author":"H Zhao","year":"2016","unstructured":"Zhao H, Leppert JT, Peehl DM. A protective role for androgen receptor in clear cell renal cell carcinoma based on mining TCGA data. PLoS ONE. 2016;11:e0146505. https:\/\/doi.org\/10.1371\/journal.pone.0146505.","journal-title":"PLoS ONE"},{"key":"2252_CR60","doi-asserted-by":"publisher","first-page":"e20175","DOI":"10.1016\/j.heliyon.2023.e20175","volume":"9","author":"Y Ren","year":"2023","unstructured":"Ren Y, Guo W, Qiao B. Abnormal expression of CEBPB promotes the progression of renal cell carcinoma through regulating the generation of IL-6. Heliyon. 2023;9:e20175. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20175.","journal-title":"Heliyon"},{"key":"2252_CR61","doi-asserted-by":"publisher","first-page":"102231","DOI":"10.1016\/j.bbrep.2025.102231","volume":"44","author":"Y Ren","year":"2025","unstructured":"Ren Y, Wei M, Tian Q, Guo W. CEBPB as a prognostic biomarker and its association with immune cells in clear cell renal cell carcinoma. Biochem Biophys Rep. 2025;44:102231. https:\/\/doi.org\/10.1016\/j.bbrep.2025.102231.","journal-title":"Biochem Biophys Rep"},{"key":"2252_CR62","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/s41419-021-04366-4","volume":"12","author":"L-J Gong","year":"2021","unstructured":"Gong L-J, Wang X-Y, Yao X, Wu X, Gu W-Y. CircESRP1 inhibits clear cell renal cell carcinoma progression through the CTCF-mediated positive feedback loop. Cell Death Dis. 2021;12:1081. https:\/\/doi.org\/10.1038\/s41419-021-04366-4.","journal-title":"Cell Death Dis"},{"key":"2252_CR63","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.18632\/aging.204607","volume":"15","author":"X Yang","year":"2023","unstructured":"Yang X, Mei C, Nie H, Zhou J, Ou C, He X. Expression profile and prognostic values of GATA family members in kidney renal clear cell carcinoma. Aging (Albany NY). 2023;15:2170\u201388. https:\/\/doi.org\/10.18632\/aging.204607.","journal-title":"Aging (Albany NY)"},{"key":"2252_CR64","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-022-01607-8","volume":"21","author":"Z Xu","year":"2022","unstructured":"Xu Z, Chen S, Liu R, Chen H, Xu B, Xu W, et al. Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway. Mol Cancer. 2022;21:146. https:\/\/doi.org\/10.1186\/s12943-022-01607-8.","journal-title":"Mol Cancer"},{"key":"2252_CR65","doi-asserted-by":"publisher","first-page":"147910","DOI":"10.1016\/j.gene.2023.147910","volume":"893","author":"J Wu","year":"2024","unstructured":"Wu J, Zhu S, Lin R, Cai W, Lin H, Wu J, et al. LINC00887 regulates malignant progression and T-cell chemotaxis in clear cell renal cell carcinoma by activating CD70 via recruitment of SPI1. Gene. 2024;893:147910. https:\/\/doi.org\/10.1016\/j.gene.2023.147910.","journal-title":"Gene"},{"key":"2252_CR66","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3892\/mmr.2014.2766","volume":"11","author":"Z Liu","year":"2015","unstructured":"Liu Z, Lu Y, He Z, Chen L, Lu Y. Expression analysis of the estrogen receptor target genes in renal cell carcinoma. Mol Med Rep. 2015;11:75\u201382. https:\/\/doi.org\/10.3892\/mmr.2014.2766.","journal-title":"Mol Med Rep"},{"key":"2252_CR67","doi-asserted-by":"publisher","first-page":"776824","DOI":"10.3389\/fonc.2021.776824","volume":"11","author":"Y Tong","year":"2021","unstructured":"Tong Y, Yu Y, Zheng H, Wang Y, Xie S, Chen C, et al. Differentially expressed genes in clear cell renal cell carcinoma as a potential marker for prognostic and immune signatures. Front Oncol. 2021;11:776824. https:\/\/doi.org\/10.3389\/fonc.2021.776824.","journal-title":"Front Oncol"},{"key":"2252_CR68","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s42003-025-07695-8","volume":"8","author":"M M\u00fcller","year":"2025","unstructured":"M\u00fcller M, Zodel K, Abhari BA, Cuomo F, Nizamuddin S, Metzger P, et al. KDM5C and KDM5D mutations have different consequences in clear cell renal cell carcinoma cells. Commun Biol. 2025;8:244. https:\/\/doi.org\/10.1038\/s42003-025-07695-8.","journal-title":"Commun Biol"},{"key":"2252_CR69","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1158\/0008-5472.can-19-3870","volume":"80","author":"N Rooney","year":"2020","unstructured":"Rooney N, Mason SM, McDonald L, D\u00e4britz JHM, Campbell KJ, Hedley A, et al. RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome. Cancer Res. 2020;80:2325\u201339. https:\/\/doi.org\/10.1158\/0008-5472.can-19-3870.","journal-title":"Cancer Res"},{"key":"2252_CR70","doi-asserted-by":"publisher","first-page":"e7854","DOI":"10.7717\/peerj.7854","volume":"7","author":"Y Fu","year":"2019","unstructured":"Fu Y, Sun S, Man X, Kong C. Increased expression of RUNX1 in clear cell renal cell carcinoma predicts poor prognosis. PeerJ. 2019;7:e7854. https:\/\/doi.org\/10.7717\/peerj.7854.","journal-title":"PeerJ"},{"key":"2252_CR71","doi-asserted-by":"publisher","first-page":"450621","DOI":"10.1155\/2014\/450621","volume":"2014","author":"Z Xiong","year":"2014","unstructured":"Xiong Z, Yu H, Ding Y, Feng C, Wei H, Tao S, et al. RNA sequencing reveals upregulation of RUNX1-RUNX1T1 gene signatures in clear cell renal cell carcinoma. BioMed Res Int. 2014;2014:450621. https:\/\/doi.org\/10.1155\/2014\/450621.","journal-title":"BioMed Res Int"},{"key":"2252_CR72","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13148-026-02055-7","volume":"18","author":"L Iisager","year":"2026","unstructured":"Iisager L, Lindgaard C, Ahrenfeldt J, Jespersen J, Kondrup K, Zanini L, et al. Epigenomic subtypes and prognostic methylation signatures in clear cell renal cell carcinoma. Clin Epigenetics. 2026;18:30. https:\/\/doi.org\/10.1186\/s13148-026-02055-7.","journal-title":"Clin Epigenetics"},{"key":"2252_CR73","doi-asserted-by":"publisher","first-page":"e24031","DOI":"10.1002\/jcla.24031","volume":"35","author":"X Jing","year":"2021","unstructured":"Jing X, Xu G, Gong Y, Li J, Lingfeng W, Zhu W, et al. A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma. J Clin Lab Anal. 2021;35:e24031. https:\/\/doi.org\/10.1002\/jcla.24031.","journal-title":"J Clin Lab Anal"},{"key":"2252_CR74","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12935-025-04016-1","volume":"26","author":"HA Rizk","year":"2025","unstructured":"Rizk HA, Said NHE, Radwan AF, Abd-Elmawla MA, Elfar N, Nassar K, et al. Exploring the role of long non-coding RNAs in renal cell carcinoma: insights into signaling pathways. Cancer Cell Int. 2025;26:53. https:\/\/doi.org\/10.1186\/s12935-025-04016-1.","journal-title":"Cancer Cell Int"},{"key":"2252_CR75","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12935-021-01805-2","volume":"21","author":"H Shen","year":"2021","unstructured":"Shen H, Luo G, Chen Q. Long noncoding RNAs as tumorigenic factors and therapeutic targets for renal cell carcinoma. Cancer Cell Int. 2021;21:110. https:\/\/doi.org\/10.1186\/s12935-021-01805-2.","journal-title":"Cancer Cell Int"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02252-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02252-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:06:30Z","timestamp":1791950790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02252-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2252"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02252-4","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"8 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the ethical committee of Eberhard Karls University T\u00fcbingen and Hanover Medical School (No. 128\/2003\u00a0V and 1213\u20132011, approved 14 October 2011). All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in this study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"185"}}